NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
12/13/2022
Back to search
Official data from USPTO
SYNOX THERAPEUTICS
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: CombinedOffice: United States
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
17
Latest update
12/13/2022
Trademark type
Combined
Nice classes
5
Filing date
06/01/2021
Registration date
12/13/2022
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
12/13/2022
Last transaction
12/13/2022
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Filing basis
Foreign priority
Drawing code
3
Owner type
99
Owner location
Dublin, IE
Examiner
KLEINMAN, CORINNE ANNE
Law office
N40
Current location
PUBLICATION AND ISSUE SECTION
Mark description
The mark consists of large lowercase and uppercase letters spelling "SynOx" above the word "Therapeutics" in a smaller font below and to the right hand side, inside 3 imperfect circles.
Holders and representatives
Holders
SynOx Therapeutics Limited
Representatives
Patrice P. Jean HUGHES HUBBARD & REED LLP
Technical classification
Nice Classes
Class 5
Vienna Codes
No Vienna codes available.
Goods and services
Class 5
Humanised antibody-based drugs for the treatmentdiagnosisdetection and/or prevention of cancer and/or other oncologicalautoimmune and inflammatory diseases; pharmaceutical productshumanised antibody emactuzumab targeting the CSF1R (colony stimulating factor 1 receptor) in cancer for the treatment of cancer and inflammatory diseases; pharmaceutical productsinhibitors of CSF1R and macrophage function for the treatment of cancer and/or other oncologicalautoimmune and inflammatory diseases; pharmaceutical productsinhibitors of protein arginine methyl-transferase (PRMT) for the treatment of TGCT (tenosynovial giant cell tumour)/PVNS (pigmented villonodular synovitis); pharmaceutical compounds for the treatmentdiagnosisdetection and/or prevention of cancer and/or other oncologicalautoimmune and inflammatory diseases; pharmaceutical productspreparations and substances for the treatmentdiagnosisdetection and/or prevention of cancer and/or other oncologicalautoimmune and inflammatory diseases; biological preparations and substances for the treatmentdiagnosisdetection and/or prevention of cancer and/or other oncologicalautoimmune and inflammatory diseases
Publications
History of USPTO decisions and trademark events.
17 publications found
R.PR
REGISTERED-PRINCIPAL REGISTER
12/13/2022
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
09/27/2022
PUBO
PUBLISHED FOR OPPOSITION
09/27/2022
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
09/07/2022
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
08/23/2022
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
08/12/2022
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
08/12/2022
ALIE
ASSIGNED TO LIE
08/12/2022
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
07/19/2022
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
02/22/2022
GNRT
NON-FINAL ACTION E-MAILED
02/22/2022
CNRT
NON-FINAL ACTION WRITTEN
02/22/2022
DOCK
ASSIGNED TO EXAMINER
02/15/2022
MDSC
NOTICE OF DESIGN SEARCH CODE E-MAILED
08/26/2021
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
08/25/2021
NWAP
NEW APPLICATION ENTERED
06/04/2021
Continuous trademark protection
Get notified about every new filing that threatens SYNOX THERAPEUTICS or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.